- Measles, mumps, and rubella are viral infections acquired through inhalation of or contact with infected respiratory droplets.
- Risk is high for travelers, especially in countries with low vaccination rates; risk for mumps is variable but remains high in many countries, including in many industrialized countries.
- Symptoms for measles include cough, eye irritation, runny nose, spreading red rash, and white lesions in the mouth. Mumps presents with swelling of salivary glands on both sides of the face and nonspecific symptoms. Rubella presents with a rash, generalized swollen glands, eye irritation, joint pain, and fever.
- Consequences of measles include severe pneumonia and brain inflammation, leading to death. Mumps after puberty can cause painful swelling of the testicles. Rubella acquired during pregnancy can result in severe complications of the eyes, heart, ears, and nervous system in the baby.
- Prevention includes observing good respiratory hygiene measures (cough and sneeze etiquette) and frequent, thorough handwashing.
- All individuals 12 months and older, born in 1957 or later, without history of disease or of 2 countable doses of live vaccine at any time during their lives should complete a lifetime total of 2 doses of measles, mumps, rubella (MMR) vaccine (spaced by at least 28 days). All infants age 6-11 months should receive 1 dose of MMR vaccine.
- Vaccine side effects are most commonly fever, rash, and local reactions.
- Duration of vaccine protection is lifelong; no booster is required.
Measles (rubeola; red measles), mumps, and rubella (German measles) are contagious viral infections spread from person to person through inhalation of or contact with infected respiratory droplets. These infections, each of which can have severe complications, occur nearly worldwide, and risk is greatest for unvaccinated travelers, especially for those exposed in countries with low vaccination rates. Humans are the only known natural host for these viruses.
Measles has been eliminated in the Americas, and the Western Pacific Region is approaching its measles elimination goal. However, large outbreaks continue to occur in Africa, the eastern Mediterranean region, Europe (western and eastern), and Southeast Asia. In the U.S., about 130 cases are reported annually, mostly after international travel by unvaccinated travelers.
Mumps occurs worldwide and remains a common disease in many parts of the world. Large outbreaks continue to occur in North America, Brazil, Australia, and New Zealand.
Rubella occurs worldwide; however, the Americas has eliminated indigenous rubella. In the U.S., rubella virus transmission in the local population has been eliminated, but imported cases occur.
Measles, mumps, and rubella viruses are primarily transmitted person to person through inhalation of or contact with infected respiratory droplets, saliva, or contaminated surfaces.
Risk is increased for unvaccinated travelers especially those going to countries with low vaccination rates, including many countries in Western Europe. The risk of exposure to mumps among travelers is variable but remains high in many countries, including in many industrialized countries.
Symptoms of measles commonly appear about 7 to 21 days following exposure and include cough, eye irritation, runny nose, a red rash starting at the head and spreading to the trunk and limbs over 3 to 4 days, and white lesions in the mouth, which appear 1 to 2 days prior to the rash.
Symptoms of mumps develop about 12 to 25 days following exposure and include swelling of salivary glands on both sides of the face that may be preceded by several days of fever, headache, weakness and fatigue, muscle aches, and loss of appetite. Mumps infection can be very severe if contracted in adulthood.
Symptoms of rubella include rash, generalized swollen glands, eye irritation, joint pain, and slight fever.
Consequences of Infection
Measles can result in severe pneumonia, diarrhea, and brain inflammation, leading to death. Painful swelling of the testicles commonly occurs with mumps acquired after puberty. Rubella acquired before birth is associated with severe complications involving the eyes, heart, ears, nervous system, and blood, as well as growth disturbances.
Need for Medical Assistance
Susceptible persons who have been exposed to or develop a red rash or symptoms of measles, mumps, or rubella should seek medical attention for evaluation of the need for postexposure prevention or treatment. Measles, mumps, and rubella (MMR) vaccine or immune globulin if given (depending on the person's age and the time since exposure) may reduce the duration and severity of illness.
Observe good respiratory hygiene measures (cough and sneeze etiquette) and frequent, thorough handwashing.
Vaccination is the best available tool for preventing measles, mumps, and rubella. MMR vaccine is a routine childhood vaccination and is also given to individuals (especially travelers) born in 1957 or later (1970 or later in Canada and the U.K.; 1966 or later in Australia), without evidence of disease or of 2 countable doses of live vaccine at any time during their lives.
Duration of protection for measles and rubella is lifelong with 2 doses of MMR vaccine, whereas protection against mumps gradually declines.
The most common side effects following MMR vaccination include injection-site reactions (pain, redness, or rash), fever, swollen lymph nodes, as well as an increased risk of seizure (due to fever) about 8 to 14 days after vaccination.
Persons with underlying medical conditions or who have concerns about the vaccine should speak to their health care provider before vaccine administration.
MMR vaccine is given as follows:
- Routine, regardless of travel for children 12 months and older: 2 doses, given at 12-15 months of age and 4-6 years of age.
- Travelers 12 months and older without history of disease or of 2 countable doses of live vaccine at any time during their lives: 1 dose or 2 doses given at least 28 days apart prior to travel in order to complete a lifetime total of 2 doses.
- Children 6-11 months of age: 1 dose prior to travel regardless of destination country or in outbreak situations. This dose is noncountable and the child will still need to receive 2 doses at the recommended ages (at least 28 days apart).
- Two lifetime doses before departure will provide protection for healthy persons. A third dose may be given during specific mumps outbreak situations.